Feature|Articles|September 17, 2024
- Pharmaceutical Executive: September 2024
- Volume 44
- Issue 9
Pharmaceutical Executive: September 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
A Care Sea Changeover 1 year ago
Jan van de Winkel: Antibody Ascensionover 1 year ago
Biotech Performance Pivot May Be in the Offingover 1 year ago
Delivery and Disruption: Navigating a Changing Care Terrainover 1 year ago
Outsourcing’s Evolution in the Pharma Industryover 1 year ago
A Risk-Reward Reset: Getting Serious About Social Mediaover 1 year ago
Copay Adjustment Chess Match: What Will Payers Do Next?over 1 year ago
Rx Power Struggle: How Pharma can Flip the PBM ScriptAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5